Abstract
Cardiovascular diseases (CVD) are the major causative factors for high mortality and morbidity in developing and developed nations. The biomarker detection plays a crucial role in the early diagnosis of several non-infectious and life-threatening diseases like CVD and many cancers, which in turn will help in more successful therapy, reducing the mortality rate. Biomarkers have diagnostic, prognostic and therapeutic significances. The search for novel biomarkers using proteomics, bio-sensing, micro-fluidics, and spectroscopic techniques with good sensitivity and specificity for CVD is progressing rapidly at present, in addition to the use of gold standard biomarkers like troponin. This review is dealing with the current progress and prospects in biomarker research for the diagnosis of cardiovascular diseases.
Expert opinion.
Fast diagnosis of cardiovascular diseases (CVDs) can help to provide rapid medical intervention, which can affect the patient’s short and long-term health. Identification and detection of proper biomarkers for early diagnosis are crucial for successful therapy and prognosis of CVDs. The present review discusses the analysis of clinical samples such as whole blood, blood serum, and other body fluids using techniques like high-performance liquid chromatography-LASER/LED-induced fluorescence, Raman spectroscopy, mainly, optical methods, combined with nanotechnology and micro-fluidic technologies, to probe patterns of multiple markers (marker signatures) as compared to conventional techniques.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The American Heart Association (AHA), in its latest report, has published up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors which include core health behaviors (smoking, physical activity [PA], diet, and weight) and health factors (cholesterol, blood pressure [BP], and glucose control) (Tsao et al. 2022). Cardiovascular diseases (CVD-s) produce immense health and economic burdens and are the number 1 “Killer” disease all over the world. The term CVD-s includes a range of major clinical heart and circulatory disease conditions (stroke, congenital heart disease, rhythm disorders, subclinical atherosclerosis, coronary heart disease, heart failure [HF], valvular heart disease, venous disease, and peripheral artery disease) and results in a humongous healthcare burden costing hundreds of billions of dollars, not including the cost of nursing home care and billions lost in productivity (indirect costs) due to premature CVD mortality. (Tsao et al. 2022) (Mokou et al. 2017).
The prevention of CVD demands maintaining a proper lifestyle and monitoring of risk factors like inflammation, diabetes, etc. (Satoh et al. 2019). The early diagnosis of CVD has a pivotal role in the patient health. Preliminary diagnosis of acute coronary syndrome (ACS) is carried out depending upon the four factors: (i) clinical history, including age, cardiac history, sex, etc., (ii) physical examination, which includes pale skin color, hypotension, cool skin, etc., (iii) ECG variation, and (iv) cardiac biomarker test. The diagnosis will be confirmed for the possible ACS patients using the methods such as echocardiogram (ECHO), treadmill test (TMT), coronary angiography (CAG), etc. The detection of a suitable biomarker in body fluids has high potential in further evaluation of the severity of the disease and can be very useful for improving the accuracy of CVD diagnosis and in prognosis, therapy planning, and follow-up (A.J. et al. 2013). The biomarkers may also help in understanding the pathophysiology of diseases (Sahu et al. 2011). As per the World Health Organization (WHO), a biomarker is stated as “almost any measurement reflecting an interaction between a biological system and a potential hazard, which may be chemical, physical, or biological. The measured response may be functional, physiological, biochemical at the cellular level, or a molecular interaction” (Strimbu and Tavel 2010). An ideal biomarker is expected to be highly sensitive, specific, and cost effective. A novel biomarker can be validated depending upon its features like sensitivity, accuracy, reproducibility in desired procedure specific to the particular outcome, easy to be used by clinician, and acceptable by the patient (Vasan 2006; Dhingra and Vasan 2017). There are two approaches for biomarker detection; one is knowledge based and the other is unbiased detection. The knowledge-based approach includes an understanding of the biological process and also improving the existing assay methods for the detection of known biomarkers. The unbiased approach includes the application of existing technologies to scroll over the molecules for biomolecular profile characterization of the disease state. These two approaches are complementary to each other (Vasan 2006). The optical methods discussed below can be useful for both approaches.
Cardiac biomarkers
There are biomarkers, useful for the diagnosis, prognosis, monitoring of the CVD, and treatment follow-up by monitoring the outcome of specific therapies. They can also help the clinician in assessing the risk factors (Dhingra and Vasan 2017; X. Wang et al. 2020a, b). The history of cardiac biomarkers started from aspartate aminotransferase (AST) to the troponins, which are currently recognized as the gold standard biomarker. The adverse outcomes of elevated cardiac biomarkers such as CK-MB and myoglobin in coronavirus disease-19 (COVID-19) patients have also been reported (Yang et al. 2021). Multi-marker detection is, at present, gaining attention due to minimization of error in comparison with single biomarker measurements (Panteghini 2004). Measuring multiple biomarkers is found to be beneficial when compared with the single biomarker-based modalities (A., J.P., and H. 2016).
AST, lactate dehydrogenase (LDH), creatine phospho-kinase (CPK), and myoglobin were recognized as suitable biomarkers for CVD even from the early days. AST was the first biomarker identified for acute myocardial infarction (AMI). The level of AST is elevated in the blood in 3–4 h after the occurrence of AMI, peaks within 28 h, and comes to a base value within 5 days. The elevated level of AST is also found in hepatic congestion, myocarditis, pericarditis, pulmonary embolism, shock, electrical cardioversion, and tachyarrhythmias. AST exists in two isoforms in tissue, one in mitochondria (m-AST) and second in cytoplasm (c-AST). Among the isoforms of AST, M-AST was more suitable for the detection of MI (Yardim 2019; Danese and Montagnana 2016).
Lactate dehydrogenase (LDH) is also proposed as a marker for AMI. Among the five isoforms of LDH, the ratio of LDH1 to LDH2 is reported to be specific for MI. LDH is elevated in the blood within 10 h after the occurrence of AMI; its value peaks within 144 h and comes to baseline value within 12 days. Other than the heart, LDH is expressed in organs like the liver, lung, erythrocytes, and kidney, thus making it less specific (Garg et al. 2017; Danese and Montagnana 2016).
Creatine phospho-kinase is known to be a biomarker for cardiac injury. Its level increases in the blood within 3–9 h after the occurrence of AMI, increases within 20 h, and attains baseline within 72 h. Later, its relation to the severity of MI and prognosis value was discovered. It lacks specificity due to its presence in the liver, kidney, skeletal muscles, and biliary tract diseases. It is available in three isoforms, CK-MB, CK-MM, and CK-BB, originating from muscle (M) and brain (B). According to the studies, it is found that CK-MB is more specific to cardiac injury compared with other isoforms of CK. CK-MB activity is also associated with skeletal muscle disorders thus having less specificity (Lewandrowski, Chen, and Januzzi 2002; Hedges R. Jerris, Hoekstra W. James 1996; Kleiman et al. 2002).
Myoglobin level may increase within an hour of myocardial cell death and is used to know the extent of MI. Its concentration peaks within 4 to 6 h and return to a base value in a day and a half in the blood. Since it clears from the blood rapidly, it is not useful for patients who are presented late. It is also found in skeletal muscular dystrophy, inflammation (myositis) or the presence of acute or chronic renal failure, and trauma thus reducing specificity. It can also increase in the case of strenuous exercise, muscle injections, and in the presence of drugs or toxins (Moe and Wong 2010; Brian Gibler et al. 1987; Lewandrowski, Chen, and Januzzi 2002).
Cardiac troponin is now recognized as the “Gold Standard” for many cardiac conditions (20–23). The importance of troponin for cardiovascular disease diagnosis has been recognized since 1987. Cardiac troponin has 3 isoforms, troponin T which attaches troponin complex to actin filament; troponin C has a calcium-binding site; and troponin I inhibits the interaction of myosin heads in the absence of calcium ions. The cardiac and skeletal muscles are synthesized by troponin C. Troponin I and T are also called cardiac troponins due their high specificity to cardiac myocytes (Jeremias and Gibson 2005). The half-life of troponin in plasma is about 2 h. The peak value of troponin is at 12 h and remains for 10 days or more. The extent of myocardial injury and likelihood of being affected by AMI can be quantitatively known by troponin measurement. Troponin T can help to predict coronary disease even in the presence of renal dysfunction (Aviles, R.J., A SKARI T. A RMAN T. 2002). If the troponin value is negative in highly sensitive troponin assays during patients’ presentation to the emergency department, and persists the same for 3 h, then 99% of patients can be excluded from the AMI prediction. Troponin is released to the circulatory system due to many factors such as apoptosis, normal cell turnover, myocyte necrosis, etc. The sensitivity of troponin depends upon cause of its release to circulatory system and technique with which it is being detected. It cannot differentiate between type I and type II myocardial infarction. Elevation of troponin can be found in patients with pulmonary embolism, sepsis or hypertensive emergencies thus making it less sensitive (Allahham, Singh, and Jneid 2019) (Bucciarelli-Ducci et al. 2004). Table 1 gives an account of currently known biomarkers of CVD.
Omic techniques for the detection of cardiac biomarkers
Biomarker detection in body fluids is an active area of research at present, due to its screening capability. The omic techniques (genomics, proteomics, metabolomics, breathomics, volatilomics, etc.) can be used for understanding the various molecular processes and understanding the correlation between the molecular species produced in an abnormal condition. The advancement in omic techniques helps in the analysis of complex samples with very little compromise on sensitivity and specificity (97) (Schneider and Orchard 2011) (X. Zhang et al. 2007). The omic techniques help in better understanding the pathophysiology of conditions like CVD and along with that provide a good platform for the detection of new biomarkers (Leon-mimila et al. 2019).
Genomics deals with the study of genes, in order to understand the role of genes in disease induction and progression. Some of the single-nucleotide polymorphisms are found to be related to coronary artery disease (CAD) (de Franciscis et al. 2016). The RNAs are studied in transcriptomics and messenger RNAs are the most investigated ones (de Franciscis et al. 2016) (Bank et al. 2015). The plasma concentrations of microRNAs (miRNAs) like miR-1, miR-133, miR-208a, and miR-499 are found to be increased in MI patients. Lower levels of miR-126 is found in CAD (de Franciscis et al. 2016). The role of miR-34 and miR-24 in the progression of MI has been studied by Zhen Wang et al. (Z. Wang et al. 2020a, b). Dongying Zhang et al. have studied the regulatory mechanisms of miR-519d-3p and Hox transcript antisense intergenic RNA (HOTAIR) in MI rats. From their experimental studies, they concluded that it can be used in MI diagnosis and therapy (Dongying Zhang et al. 2019). Pirouzpanah et al. have reported the diagnostic value of miRNA 21 for AMI (Pirouzpanah and Mohammad 2019). In patients with HF, the upregulation of miR5571-5p, miR-3135b, and miR3908 has been observed (F. Chen et al. 2018). Cosentino et al., in their study, observed the diagnostic and prognostic effect of mitochondrial biomarkers such as cytochrome C and cell-free mitochondrial DNA in STEMI patients. The mitochondrial biomarkers were found to be complementary to the troponins in acute ventricular dysfunction (Cosentino et al. 2021).
Small molecules (< 1500 Da) like peptides, amino acids, and carbohydrates are studied in metabolomics. Metabolomics can be used to identify various metabolites which are linked to CVD (Tuteja and Rader 2012). Amino acids like tyrosine, valine, phenylalanine and leucine are predicted to be associated with diabetes which is one of the risk factors of CVD. Higher concentrations of serum proteins, monounsaturated fatty acids, and phenylalanine along with reduced level of polyunsaturated fatty acids are found to be indicators of CVD (Tuñón et al. 2016). Christine et al., has studied the n-3 fatty acids and vitamin D supplementation effects in cardiac biomarker and inflammation in diabetes patients. The study concluded that the supplementation of vitamin D3 and n-3 fatty acid did not alter the concentration of inflammatory biomarkers in type-2 diabetes patients (Limonte et al. 2021).
Proteomics deals with (i) identification of proteins, (ii) protein profiling, (iii) determination of protein structures, (iv) protein–protein interaction, (v) protein quantification, and (vi) post-translation modification (Lindsey et al. 2015). Proteomics can provide details about the state of the cell, tissue, and organ (Lindsey et al. 2015). Even with the advancement of technologies, the sensitive detection of low abundant proteins, complex protein mixture analysis, quantification of protein, etc. still remains a challenging task. Thus, detection of protein biomarkers is still not easy due to the very large numbers of proteins in samples (blood serum, tissue, urine, etc.), a wide range of protein concentrations, etc. (Chandramouli and Qian 2009)(Pirouzpanah and Mohammad 2019). The posttranslational modifications (PTM) are significantly involved in the CVD process but are not easily studied by using genomics and transcriptomics (Shen et al. 2014). Studies involving the phosphorylation of troponin have been carried out in ischemic heart patients to healthy donors, illustrating the importance of PTMs (Shen et al. 2014). Proteomics studies have also been carried out after reducing the complexity of the samples by extracting the high abundant proteins like albumin, IgG, IgA, transferrin, haptoglobin, and antitrypsin (Yu et al. 2018) (H. J. Kim et al. 2011).
Spectroscopic techniques for cardiac marker detection
Surface-enhanced Raman spectroscopy
Spectroscopic techniques have been gaining attention in cardiac diagnostic applications due to their potential for rapid detection of biomarkers, with very high sensitivity. Fluorescence, surface-enhanced Raman spectroscopy (SERS), photoacoustic absorption, and surface plasmon resonance (SPR) have been always at the forefront of clinical spectroscopy due to the enormous possibility of translating into point-of-care (POC) devices. These techniques have been highly beneficial for biomarker detection due to their rapid, label-free detection with minimal or no sample processing protocol. Raman spectroscopy is a vibrational spectroscopic tool which can provide information regarding the biological entities and their environment by evaluating the inelastically scattered light properties originating from samples upon laser excitation. The low sensitivity of the conventional Raman spectroscopic technique which has got lower detection limits can be overcome by the use of metallic nanoparticles or rough, specially designed, metallic substrates in what is termed surface-enhanced Raman spectroscopy. The combination of electromagnetic field enhancement and charge transfer mechanism involved in this technique can provide for the Raman signal enhancement up to 1014 or more, even down to a single molecule (Langer et al. 2019) (Kneipp et al. 1998)(John et al. 2022).
Chon et al. have introduced a rapid, sensitive approach for the simultaneous detection of cardiac markers, troponin, and creatine kinase using SERS immunoassay measurements. This competitive immunoassay employing the combination of SERS nanotags and magnetic beads was effective in the detection of 2.5 and 33.7 pg/mL for creatinine kinase and troponin respectively (Choo 2014). This methodology was claimed to be less influenced by sample matrix effects and also does not demand any pre-processing approaches like filtration and centrifugation. Another rapid, cost-effective SERS immunoassay approach developed by Su et al. has been capable of simultaneous detection of three biomarkers (cardiac troponin I (cTnI), N-terminal prohormone of brain natriuretic peptide (NT-ProBNP), and neutrophil gelatinase-associated lipocalin) with minimal sample volume (Su et al. 2018). Further, they have obtained a LOD of 0.76, 0.53, and 0.41 fg/mL for cTnI, NT-ProBNP, and NGAL, respectively, and later, the assay was validated in the blood plasma collected from the patients, which affirms the potential of this technique for POC clinical diagnostics (Su et al. 2018). Another interesting SERS lateral immunoassay introduced by Fu et al. has explored the use of graphene oxide–gold nanoparticle complex for efficient signal amplification for troponin detection. This assay was able to perform quantitative detection of troponin at a significantly lower range (5 pg/mL to 1000 ng/mL) which was otherwise not in the achievable limit of immunoassay without graphene oxide (Xiuli et al. 2018). In order to circumvent the limitations with the measurement of SERS nanoprobes in biological solutions, Garza et al. have designed and developed a novel SERS collection device which can consistently gather the nanoprobes for SERS measurement. The precipitation of nanoprobes created in solutions can move away from the laser excitation spot during the usual SERS measurements, which results in smaller number of sample molecules, affecting sensitivity. The sensing approach by Garza et. al. demonstrated an enhancement in SERS signal intensity of cardiac troponin with respect to the traditional nanoprobes in solution approach. Researchers have also encoded SERS nanotags with lateral flow assay immunostrips to generate ultrasensitive POC, multiplex detection of cardiac markers (Garza and Cote 2017) (Di Zhang et al. 2018). The use of SERS encoded with lateral flow assay (LFA) strips with one test line has resulted in the reduction in cost, complexity of operation, sample volume, and reagent consumption (Di Zhang et al. 2018). S. Mabbot et. al. have fabricated a paper-based microfluidic assay for the detection of miR-29a, a micro-RNA (miRNA) biomarker of CVD (Mabbott et al. 2019). The device comprising dual analytical readouts (colorimetric and SERS) was proposed to be a viable option for point-of-care detection of miRNA circulating freely in the bloodstream. An LOD of 47 pg /μL has been obtained using this SERS test. Aptamer-based SERS biosensing platforms have been also reported capable of detecting cTnI as low as 10 ng/ml. A. Waleed et. al. have reported myoglobin detection in buffer and urine samples by constructing a 3D silver anisotropic nano-pine tree array-modified indium tin oxide SERS substrate (El-said et al. 2016). Benford et al. have developed a SERS-based biosensor consisting of a nanofluidic channel for the detection of multiple analytes (brain natriuretic peptide, troponin I, and C-reactive protein). SERS hot spots in the measurement region of the nanofluidic channel were generated with the help of high-density aggregated gold nanoparticles ~ 60 nm in size (Benford et al. 2009). A recent SERS assay work have employed gold patterned array chip and core–shell nanoparticles for the ultra-sensitive duplex detection of cardiac troponin I (cTnI) and creatine kinase-MB from serum samples. The developed assay method has the detection limit for cTnI and creatine kinase-MB as 8.9 pg/mL and 9.7 pg/mL respectively, which is highly sensitive than the traditional fluorescence or ELISA approaches. (Cheng et al. 2019). The SERS technique has been also employed for the quantitative detection of heart-type fatty acid-binding protein (Ma et al. 2019). This technique which obtained a LOD ~ 1.4490 ng/mL was better than the conventional ELISA and colloidal gold immunochromatography techniques in terms of sensitivity, time consumption, and ease of operation. M. Shorie et al. have developed gold nanoparticle–tungsten disulfide SERS substrate which can facilitate combined effects of chemical and electromagnetic properties for multifold Raman signal enhancement of probe molecules (Shorie et al. 2018). The nanohydrid (Gold nanoparticles (AuNPs) are assembled on exfoliated tungsten disulfide nanosheets (WS2)) substrate has been effective in obtaining a detection limit ~ 10−2 pg/mL for myoglobin, which is sufficient enough for clinical applications. A recent SERS work using Au core–Ag shell nanotags has obtained a detection limit of 9.80 pg/mL for troponin with high specificity. The detection, carried out using a portable Raman device, was fast, with minimal sample preparation and low sample volume (50 μL) and has been suggested as a reliable POC method in clinics for early detection of cardiac disorders (Shorie et al. 2018). The same research group have also used the core–shell-mediated substrate for simultaneous detection of the Heart-type fatty acid-binding protein (H-FABP) and cardiac troponin I with LOD of 0.6396 and 0.0044 ng /mL respectively (Hu 2020).
Surface plasmon resonance
The surface plasmon resonance technique basically relies on collective oscillations of surface electrons at a metal–dielectric interface, induced by light. Such metallic structures with a highly localized electromagnetic field have got high sensitivity to any changes occurring to the refractive index in the medium in contact with it. This property can be widely explored for various biosensing purposes, and thus, the SPR technique has found ubiquitous use in the detection of pathogens, biomarkers, toxins, allergens, etc. (J Lukose et al. 2016)(Jijo Lukose et al. 2018). Primo et. al have performed SPR measurements using the commercial platform Autolab SPRINGLE for the detection of galectin-3 (Gal3) with an LOD of ~ 2.0 ng /mL, a promising marker for cardiac diagnosis (Primo et al. 2018). This immunosensing technique was developed by fabricating a self-assembled layer of poly-(diallyldimethylammonium chloride) and graphene oxide (GO) on gold surface and covalently linking an orientation element (3-aminephenylboronic acid) for anti-Gal3 attachment. The use of graphene oxide has a significant impact on enhancing the sensing performance whereas the orientation element resulted in increased specificity for the anti-Gal3 towards Gal3 binding. Au/sodium 3-mercapto-1-propane- sulfonate (MPS) was made to interact with a PDDA solution for about 15 min. Then Au/MPS/PDDA solution was made to interact with a GO solution for 30 min. The multilayer system (Au/MPS/(PDDA/GO)n) was obtained by repeating the procedure n times. EDC/NHS mixture was used to activate the GO carboxyl residue and left to interact with 3-aminephenylboronic acid (3ABA) solution for amidation reaction. The non-reacted residue was quenched in ethanolamine (EtNH2) solution. A BSA solution was used in Au/MPS/(PDDA/GO)n/3ABA/anti-Gal3, for blocking the non-absorbing sites, and the procedure is described in Fig. 1. This SPR technique has also displayed higher selectivity while performing experiments in human serum samples (Primo et al. 2018). Jang et al. have utilized nanoparticle-enhanced SPR methodology for the detection of marker protein B-type natriuretic peptide (BNP), in the range 1 aM to 500 nM (Jang et al. 2014). This sandwich immunoassay was fabricated using aptamer functionalized metallic surface in combination with gold nano-cubes attached with antibody and carried out measurements successfully in buffer and undiluted serum sample. Liu et al. have carried out troponin detection using an SPR biosensor with anti-fouling ability for specific attachment of target biomarkers (Tsai et al. 2011). Even though the detection was carried out in less than 2 min, the detection limit (100 ng/mL) obtained was not sufficient enough to be used for measurements with clinical samples. Troponin measurements using commercial SPR platforms (K-MAC micro SPR model, Korea and (AutoLab Spirit®, Eco Chemie, The Netherlands)) have also obtained comparable performance with that of ELISA assays (Y. Kim and Kwon 2011) (Fireman and Tatsuo 2007).
Wu et al. have achieved ultrasensitive troponin detection using magnetic field–assisted SPR immunoassay approach (Fig. 2). The technique involving a magnetic immune probe has obtained 1.25 ng/mL detection limit for troponin, which was ~ 1000-fold better than the traditional polydopamine-based SPR assays (Wu et al. 2017). Kurita et al. have reported trace level detection of BNP peptide (15 fg) in 30 min. time by using a combined microfluidics-SPR approach (Kurita et al. 2006). Masson et al. have fabricated a SPR-based fiber optic probe for myoglobin and cardiac troponin I sensing within ten minutes time and detection limits of 1.4 and 2.9 ng/ml respectively (Masson et al. 2004). Tadepilli et al. have fabricated plasmonic paper based sensor capable of detecting troponin I in human serum and sweat samples (Tadepalli et al. 2015). The short peptide based plasmonic sensors are suggested as reliable point of care sensors, due to their high thermal stability, longer shelf life and high sensitivity. Similarly, LSPR based detection of troponin in human serum was also performed by Ding et al. using nanoimprinted, large surface area, nanohole array biosensor chips (Ding et al. 2015). The sensor showed high reproducibility in measurements and have also obtained an LOD of 0.55 ng/ml. Liyanage et al. have fabricated gold nano-prisms functionalized with anti-cTnT for the detection of troponin with atto-molar detection limit (Liyanage and Andeep 2017). Magnetic nanoparticles due to their high refractive index and high molecular weight can enhance the LSPR response of metallic nanoparticles for biosensing (Tang et al. 2013). Tang et al. have demonstrated this by using Fe3O4 magnetic nanoparticles along with gold nano-rods for troponin sensing from blood plasma (Tang et al. 2013). This resulted in a significant increase in the LSPR shift upon troponin binding (~ sixfold) followed by a detection limit down to picomolar level. In his previous work, Tang et al. have used a mixture of gold nanorods with tunable plasmon band for the simultaneous detection of troponin and myoglobin from sample solution (Tang and Casas 2014). The use of gold nanorods have been found beneficial for plasmonic sensing due to their ease of synthesis and the ability for creating tunable resonance band by varying the size and aspect ratio during synthesis. In addition, the background noise of endogenous chromophores from biological mixtures (e.g., serum and blood) is minimal in the wavelength range used. Huang et al. have incorporated LSPR approach integrated into a four channel microfluidic biosensing device for the multiplex detection of inflammatory biomarkers from ~ 60 μL of assay volume (J.-S. Chen 2020). The proof-of-concept model demonstrated IgG, CRP, TNF-α, and TNF-α/IgG multiplex detection in 3.5-h time. In a recent work, SPR technique has been coupled with mass spectrometry for the detection of myoglobin, the marker protein for heart muscle injury (J.-S. Chen 2020).
Breathomics
Like the “Marker Proteins” produced in abnormal conditions, the bio-molecular reactions taking place during the induction, progression, regression, and recurrence of any disease, produce many volatile molecular species, mainly “volatile organic compounds, VOCs”. These will be carried over to the lungs through the circulating blood and eventually will come out through the exhaled breath. Breath analysis, called “Brethomics” or “Volatolomics,” thus offers a very convenient method for screening, early detection, and follow-up in many diseases, including cardiovascular conditions (V. R. et al. 2021)(Kartha and Santhosh 2014)(Bykova et al. 2019)(Marcondes-Braga et al. 2016)(Ibrahim et al. 2019).
Breath analysis has thus attracted considerable interest recently, especially in view of the widespread pandemic condition of COVID-19, which often leads to many effects like Post-Covid Syndrome-PCS and Multiple Inflammatory Syndrome-Children, MIS-C, and several groups are carrying out vigorous research in developing breath analysis methods for diagnosis of cardiovascular diseases associated with such conditions. A typical application of the breath analysis technique in discriminating PCS-Post Covid Syndrome, from other conditions showing similar symptoms has been developed recently (VR et al. 2022). Figure 3 shows the classification obtained for PCS and normal breath samples using E-nose. It is clear that the breath biomarker associated with the PCS condition makes this classification in the score plot.
The main methods used for breath analysis include spectroscopic, electronic, and mass spectroscopy-coupled techniques like gas chromatography-mass spectroscopy, GC–MS, and differential mass spectrometry. Several molecules like NO, acetone, isoprene, trimethyl amine, pentane, CO, ethane, etc. have been found to be good markers for many CVD conditions (Bykova et al. 2019)(Marcondes-Braga et al. 2016) (Cikach Jr and Dweik 2012). Table 2 shows the major breath markers observed in cardiovascular diseases. Many of these molecules are indicators of diseases which may later be involved in the development of cardiac conditions and periodic monitoring of them in the breath sample can thus serve as an efficient technique for early detection of CVD. For example, acetone, which is an indicator of diabetes condition, can be easily detected by UV-PAS (Nidheesh et al. 2021). Similar studies of breath constituents like isoprene, using PAS have shown their ability for Breath analysis, where even sub-ppb levels of these molecules can be detected by the PAS method (Fig. 4), this study can be further extended for the diagnosis/monitoring of cardiac conditions.
Other methods
Blanco-Colio et al. identified soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK)—a new biomarker for CVD through SELDI-TOF MS (Blanco-Colio et al. 2011). Madeleine Johansson et al. studied the relationship between orthostatic hypotension (OH) to that of CVD. Blood samples were analyzed by antibody-based proximity extension assay technique, combined with Olink Proteomics Proseek Multiplex CVD I 96 × 96 reagents kit through which they measured 92 CVD-related protein biomarkers. They identified proteins like MMP-7, TM, MB, TIM-1, CASP-8, CXCL-1, Dkk-1, LOX-1, MCP-1, PAR-1, PIGF, and TF, associated with atherosclerosis, MI, etc. (Johansson et al. 2018).
Capillary electrophoresis in combination with mass spectrometry (CE-MS), which was used for the peptide profiling of urine sample, is a reproducible technique. Five collagen fragments were identified through capillary electrophoresis coupled to micro-TOF mass spectrometry in patients with coronary artery disease (Dawson et al. 2012). It has high resolution but low sample loading capacity. Another study gave a panel of 17 peptides identified through CE-MS with some of them being collagen fragments. The same research team has done the study with 586 urine samples using CE-MS and identified 238 discriminatory polypeptides among which were fragments of alpha-1-antitrypsin, collagen types 1 and 3, granin-like neuroendocrine peptide precursor, membrane-associated progesterone receptor component1, sodium/potassium-transporting ATPase gamma chain, and fibrinogen-alpha chain (Delles et al. 2010).
Monocyte antigen CD14 has been identified through one-dimensional SDS-gel electrophoresis followed by liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS) in patients with CAD. The validation of the same was done by ELISA in urine and serum samples (Lee et al. 2015). The levels of neutrophil gelatinase-associated lipocalin (NGAL) which is expressed in endothelial cells and modulate the activity of matrix metalloproteinase 9 (MMP9) and also an important mediator of vascular remodeling and plaque instability in atherosclerosis. C57BL/6 J control mice and atherosclerotic apolipoprotein E (apoE) low-density lipoprotein receptor (LDLR) mice were anesthetized and were given a brief hypoxic stress (10 min of 10% oxygen). Mice were allowed to come to a normal environment in 48 h. The expression of NGAL and MMP 9 was measured in the mouse 48 h later quantitatively through RT-PCR, zymography, and immunohistochemistry. The presence of NGAL and MMP9 in vascular inflammation caused by MI was suggested by the study (Hemdahl et al. 2006).
Biosensors have also been designed to detect and quantify target molecules like proteins and nucleic acids or monitor antigen–antibody interaction. A fabrication procedure generally involves immobilization of DNA, RNA, antibody, etc. on the transducer surface, which converts the interaction between the target molecules and biological elements to a quantifiable signal. Optical biosensors work based on changes in amplitude, polarization, and frequency of input light or phase change in response to the biorecognition process (Qureshi et al. 2012). In the development of optical biosensors, the selection of a proper immobilization strategy plays an important role. An immobilization strategy includes enhancing the surface area so that the biological element of interest securely fixes onto the surface, and the bioreceptor is optimally positioned (Regan et al. 2018). In one technique, p-type anatase was integrated with FET for the detection of troponin I. Demonstration of the device was done to detect the concentration of antigen troponin I in the range of 1 ng/ml to 10 μg/ml. Figure 5 depicts the FET-based immunosensor for troponin I detection (Adzhri et al. 2017). Voltamo-metric biosensor has been developed by Pourali et al., for the detection of troponin in AMI (Pourali et al. 2021). Jing Li et al. developed a silica-conjugated microcomb electrode sensor for the detection of troponin I which has the LOD of 1fM(Li et al. 2021). An aptamer-based plasmon enhanced electrochemiluminescence setup was developed for the detection of troponin I, by Kitte et al., the obtained LOD was 0.75 fg/mL (Addisu et al. 2021). Optical biosensors such as colorimetric luminescence and fluorescence biosensors use target molecules tagged with dyes which require expertise for their proper use; these biosensors are sensitive but are expensive and bulky (Qureshi et al. 2012).
Natarajan et al. developed a cellulose paper–based lateral flow immunoassay for the detection of troponin. The analytical strip is made of commercially available filter paper. The detection limit was 2.10–2.75 ng/ml (Natarajan, Jayaraj, and Prazeres 2021). Philps has developed a POC sensor, to detect and quantify the cardiac biomarker (Troponin, BNP), called Minicare. The device is based on sandwich immunoassay using magnetic beads, and the Minicare device uses frustrated total internal reflection (f-TIR) for the quantification of biomarkers. The device has a limit of detection of 18 ng/L for troponin T (156).
Fluorescence is a popular optical method for the detection and quantification of biomarkers. The specificity of the method is amplified by using labeling antibodies. The AQT90 FLEX system, developed by the Radiometer company, uses time-resolved fluorescence and immunoassay cartridge, to detect cardiac biomarkers like troponin and BNP (156). The device pylon developed by ET Healthcare also uses fluorescence for the detection and quantification of biomarkers. The device has a LOD of 1.2 ng/L for troponin (Buhot 2020).
Being an analytical tool, Fourier transform infrared (FTIR) spectroscopy has also gained high attention due to its enormous potential in investigating all kinds of samples comprising both chemical and biological species (Sala et al. 2020). In conventional FTIR spectroscopy, the IR beam will be directly transmitting over the sample of interest, whereas the variant Attenuated Total Reflection (ATR) mode (ATR) involves the monitoring of the variations in the IR radiations, once it is reflected from the sample which is kept on the top of an ATR crystal. Haas et al. have explored the potential of FTIR spectroscopy for diagnosing myocardial infarction from minimal amount of dried serum samples (Haas et al. 2010). The study comprising of the Raman data obtained from 225 healthy subjects and 342 cardiac subjects were subjected to both cluster analysis and artificial neural networking (ANN). The sensitivity and specificity for the myocardial infarcted vs healthy subjects were obtained as 98% and 97% respectively in ANN analysis. In a similar manner, 100% sensitivity and specificity was obtained for the discrimination of heart failure and myocardial infarcted classes. In another interesting work, the ATR-FTIR technique was employed for the quantitative investigation of choline from blood serum samples (Khanmohammadi et al. 2015). The elevated levels of choline in the blood of acute coronary syndrome patients have generated high interest among scientists to probe the choline concentration. The normal range of choline ~ 7–12.3 mmol/L in blood plasma will be increased significantly above 25 mmol/L for cardiac patients (Danne et al. 2007). The ATR study combined with various chemometrics tools have shown to be effective on the basis of studies performed with 82 samples. Researchers have also verified the utility of the FTIR technique for probing tissue samples in view of investigating cardiac disorders. R. Cheheltani et al. have reported FTIR imaging spectroscopy, which can assess collagen deposition in heart tissue as a result of myocardial infarction (Cheheltani et al. 2012). The study conducted on the tissues collected from rat models was effective at probing the IR characteristic band of collagen at 1338 cm−1. In another study, Zheng et al. have investigated paraffin-embedded heart samples for protein characterizing in the myocardial infarcted cases, where an enhancement in the α-helix and deduction in β-sheet of protein secondary structures were found with respect to control (Zheng et al. 2010). FTIR analysis on human atherosclerotic plaques is also reported in view of studying atherosclerosis, in which the predominance of spectral features arising from lipids, esters, fibrous tissues, and phosphate were found (Dritsa 2012). Table 3 summarizes various advantage and disadvantage of various spectroscopic techniques.
High-performance liquid chromatography-laser-induced fluorescence
We have assembled and used an ultra-sensitive high-performance liquid chromatography-laser induced fluorescence detection (HPLC-LIF) system in a protein-profiling approach for analyzing protein profiles of microliter quantities of clinical samples, such as serum, saliva, lysed cellular samples, and tissue homogenates (Venkatakrishna et al. 2003). The method is highly objective and capable of discriminating the sample under investigation as normal, pre-malignant, or malignant condition and malignancy stages. The system records the protein profile of clinical samples using a HPLC protein separation step combined with an ultra-sensitive laser-induced fluorescence (LIF) detection which provides the chromatogram, a plot of fluorescence intensity of the eluted protein versus time of elution (Bhat et al. 2010). The system can detect sub-femto-mole levels of proteins using microliter/gram amounts of a clinical sample and can give more or less complete profiles of the large number of proteins present at ultra-trace levels in these samples. Figure 6 depicts the schematic diagram of the setup. LASER (257 nm) is made to focus on the capillary flow cell through which the separated components from HPLC is made to pass. The fluorescence signal from the excited component is collected using collection optics along with a monochromator and detected using photomultiplier tube (PMT) (Bhat et al. 2010).
We have extended recently, our ultra-sensitive HPLC-LIF technique for the analysis of blood serum of CVD subjects (Rao et al. 2020). Serum protein profiles of healthy volunteers (14) and patients with different heart diseases (11) were recorded, using the HPLC-LIF system developed in our laboratory. Protein profiles of disease conditions can be seen in Fig. 7 which shows that there are significant differences in the protein peak positions and relative intensities, showing that the relative concentrations of many proteins present in normal and disease conditions are different, and that many new proteins are also formed in induction and progression of the disease. Preliminary data analysis (principal component analysis, PCA) on recorded protein profiles has given good discrimination between protein profiles of healthy subjects and patients with different heart diseases (Fig. 8a and b). Further, a detailed protein profile study using a highly sensitive HPLC-LIF system is being carried out for detecting specific markers of various cardiovascular diseases.
In our recent work, we have extended the ultra-sensitive HPLC-LIF method for the analysis of serum protein profiles of ACS samples. The blood samples (45–70 years) are collected from the patient admitted in the cardiology ICU/ward with diagnosis of ACS (ECG changes/elevated cardiac biomarker) department of cardiology, Kasturba Medical College, Manipal. Normal blood samples were collected from age matched healthy volunteers. The ethical clearance has been obtained for the study, from Institutional Ethics Committee. All samples were used with “informed consent.” A total of 17 normal samples and 32 ACS samples were collected. Experimental details have been explained elsewhere (Rao et al. 2020)(Patil et al. 2012).
Averaged protein profiles of ACS and normal samples can be seen in Fig. 9 which suggests that there are significant variations in relative intensities. Preliminary data processing by principal component analysis (PCA) has given very good discrimination between protein profiles of Normal and ACS (Fig. 10). The serum protein profile analysis gives a clear picture of the pathophysiological condition. The HPLC-LIF detection method gives a simple method, which can even allow visual discrimination between normal and abnormal samples, for early diagnosis. In the present study, PCA has given clear discrimination between ACS and normal samples with high specificity and sensitivity. Further detailed study of ACS whole blood samples is being continued using different techniques such as HPLC-LED-induced fluorescence (IF), Raman spectroscopy, fluorescence, etc.
As a typical example of the application of Protein profiling in CVD early detection, the variation in CPK from a normal-smoker-IHD subject is shown in Fig. 11. CPK-MB is a biomarker for CVD, elevation of CPK in serum is found in case of inflammation as discussed before. Tobacco consumption is one of the risk factors for CVD. Studies have suggested CPK is observed only in extremely small amounts in normal serum, while in smokers it starts to show an increase (Sujatha et al. 2006). In IHD—ischemic heart disease, its concentration in serum exceeds even that of the most abundant serum protein, HSA. Monitoring of CPK can thus serve as an efficient method for early onset CVD conditions in even regular smokers, where the marker starts to show an increase from normal.
Discussion
The delay in getting medical attention to CVD patient is a major influence on patient condition and long-term health. This situation can be minimized with the help of early or fast diagnosis of the disease. Troponin is considered to be the gold standard biomarker for CVD. Because of its poor sensitivity with current methods, there is an urgent need for reliable biomarker/biomarkers, which should be specific to the type of CVD, sufficiently sensitive, and easy to detect by clinicians. In this regard, multi marker detection combined with pattern analysis is found to be effective. Detection of markers representing each pathophysiological (inflammation, stress, plaque instability, etc.) condition of the disease may be highly desirable. One of the approaches to achieve this goal is by developing a highly sensitive method for the detection of biomarkers in body fluids such as serum, saliva, etc. The advancement in chromatographic techniques, mass spectrometry, capillary electrophoresis, nano material-based detection method, etc. has opened the doors for the detection of multiple biomarkers. Most of these techniques are still laboratory based, have poor reproducibility outside lab condition measurements, are costly, need complicated experimental setup and hence professionals to operate, etc. There is thus an urgent need for user-friendly, low-cost, simple systems with techniques for simultaneous detection of multiple biomarkers with high sensitivity and specificity, to enable more precise data analysis using Artificial Intelligence and Machine Learning methods, so that operation and diagnosis can be effective, operator-independent, needing only trained technicians that can be adaptable in hospitals and clinics. HPLC combined with laser-induced fluorescence technique can be a potential tool to analyze serum protein profiles with multi-marker diagnosis of CVDs by AI/ML methods. It should also be noted here that in addition to screening, early detection, and therapy follow-up, the technique can be used to establish the identity of the marker proteins, either by running the selected tumor markers in a co-injection technique (Patil et al. 2012) or recording the Raman/SERS spectra of the collected fractions and comparing with Spectral Data Banks.
References
A berezin E 2018 Circulating biomarkers in heart failure From Research to Clinical Practice 89–108 https://doi.org/10.1007/5584
Addisu, Shimeles, Terefe Tafese, Chen Xu, Muhammad Saqib, Haijuan Li, and Yongdong Jin. 2021. “Plasmon-enhanced quantum dots electrochemiluminescence aptasensor for selective and sensitive detection of cardiac troponin I.” Talanta 221 (September 2020): 121674. https://doi.org/10.1016/j.talanta.2020.121674
Adzhri AMK, Arshad SCB, Gopinath R, Ruslinda MFM, Fathil CI, Nuzaihan MN (2017) Enhanced sensitivity mediated ambipolar conduction with P-type TiO2 anatase transducer for biomarker capturing. Sens Actuators, A 259:57–67. https://doi.org/10.1016/j.sna.2017.03.015
Aggarwal A, Blum A, Schneider DJ, Sobel BE, Dauerman HL (2004) Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coron Artery Dis 15(8):471–475. https://doi.org/10.1097/00019501-200412000-00003
Alaaraji Shakir F T (2019) Is there a correlation between monocyte chemoattractant protein-1 with autotaxin, azurocidin-1, apolipoprotein C-III and elastase-2 in male Iraqi acute myocardial infraction patients ? Biomedical & Pharmacology Journal. 12(4):2105–21. https://doi.org/10.13005/bpj/1846
Allahham, Mahmoud, Mohita Singh, and Hani Jneid. 2019. Cardiac biomarkers in acute myocardial infarction. Biomarkers in Cardiovascular Disease. Elsevier Inc. https://doi.org/10.1016/B978-0-323-54835-9.00010-7
Anderon L (2005) Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 563(1):23–60. https://doi.org/10.1113/jphysiol.2004.080473
Andersson C, Enserro D, Sullivan L, Wang TJ, Januzzi JL, Benjamin EJ, Vita JA et al (2016) Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: the Framingham Heart Study. Atherosclerosis 248:245–251. https://doi.org/10.1016/j.atherosclerosis.2016.02.013
Anwaruddin S, Januzzi JL, Baggish AL, Lewandrowski EL, Lewandrowski KB (2005) Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 123:140–145. https://doi.org/10.1309/4BCTG5UCYMQFWBLR
Aviles RJ, A SKARI T A RMAN T et al (2002) Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med 346(26):2047–2052. https://doi.org/10.1056/NEJMoa013456
Balagopal P, De Ferranti SD, Cook S, Daniels SR, Gidding SS, Hayman LL, McCrindle BW, Mietus-Snyder ML, Steinberger J (2011) Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth: a scientific statement from the American Heart Association. Circulation 123:2749–2769. https://doi.org/10.1161/CIR.0b013e31821c7c64
Bank IEM, Timmers L, Gijsberts CM, Zhang YN, Mosterd A, Wang JW, Chan MY et al (2015) The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease. Expert Rev Mol Diagn 15(12):1577–1588. https://doi.org/10.1586/14737159.2015.1109450
Benford ME, Wang M, Kameoka J, Coté GL (2009) Detection of cardiac biomarkers exploiting surface enhanced Raman scattering (SERS) using a nanofluidic channel based biosensor towards coronary point-of-care diagnostics. InPlasmonics in Biology and Medicine VI 7192:1–6. https://doi.org/10.1117/12.809661
Bhat S, Patil A, Rai L, Kartha VB, Santhosh C (2010) Protein profile analysis of cellular samples from the cervix for the objective diagnosis of cervical cancer using HPLC-LIF. J Chromatogr B 878(31):3225–3230. https://doi.org/10.1016/j.jchromb.2010.09.025
Blake, Gavin J, and Paul M Ridker. 2003. “C-reactive protein and other inflammatory risk markers in acute coronary syndromes.” Journal of the American College of Cardiology 41 (4 Suppl S): 37S-42S. https://doi.org/10.1016/S0735-1097(02)02953-4
Blanco-Colio LM, Martín-Ventura JL, Carrero JJ, Yilmaz MI, Moreno JA, Gómez-Guerrero C, Ortiz A, Egido J (2011) Vascular proteomics and the discovery process of clinical biomarkers: the case of TWEAK. Proteomics - Clinical Applications 5(5–6):281–288. https://doi.org/10.1002/prca.201000102
Bodí V, Sanchis J, Llàcer À, Fácila L, Núñez J, Bertomeu V, Pellicer M, Chorro FJ (2005) Risk stratification in non-ST elevation acute coronary syndromes: predictive power of troponin I, C-reactive protein, fibrinogen and homocysteine. Int J Cardiol 98:277–283. https://doi.org/10.1016/j.ijcard.2003.10.046
Bonaterra G, Zugel S, Kinscherf R (2010) Novel systemic cardiovascular disease biomarkers. Curr Mol Med 10(2):180–205. https://doi.org/10.2174/156652410790963330
Borisov, Alexey V, Anna G Syrkina, Dmitry A Kuzmin, Vyacheslav V Ryabov, Andrey A Boyko, Olga Zaharova, Vyacheslav S Zasedatel, and Yury V Kistenev. 2021. “Application of machine learning and laser optical-acoustic spectroscopy to study the profile of exhaled air volatile markers of acute myocardial infarction.” Journal of Breath Research 15 (2). https://doi.org/10.1088/1752-7163/abebd4
Brian Gibler W, Gibler CD, Weinshenker E, Abbottsmith C, Hedges JR, Barsan WG, Matthew Sperling I, Chen W, Embry S, Kereiakes D (1987) Myoglobin as an early indicator of acute myocardial infarction. Ann Emerg Med 16(8):851–856. https://doi.org/10.1016/S0196-0644(87)80521-8
Brogan GX, Hollander JuddE, McCuskey CF, Thode HC, Snow J, Sama A, Bock JL (1997) Evaluation of a new assay for cardiac troponin I vs creatine kinase-MB for the diagnosis of acute myocardial infarction. Acad Emerg Med 4(1):6–12. https://doi.org/10.1111/j.1553-2712.1997.tb03636.x
Browner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86(2):631–637. https://doi.org/10.1210/jcem.86.2.7192
Brscic E, Bergerone S, Gagnor A, Colajanni E, Matullo G, Scaglione L, Cassader M et al (2000) Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up. Am Heart J 139(6):979–984. https://doi.org/10.1067/mhj.2000.106165
Bucciarelli-Ducci C, Rasile C, Proietti P, Mancone M, Volponi C, Vestri A, Fedele F (2004) Troponin I as a specific marker of myocardial injury: from theory to clinical practice in the diagnosis of acute coronary syndrome. Coron Artery Dis 15(8):499–504. https://doi.org/10.1097/00019501-200412000-00007
Buhot, Arnaud. 2020. “Recent advances in cardiac biomarkers detection: from commercial devices to emerging technologies.” Journal of Pharmaceutical and Biomedical Analysis, no. xxxx: 113777. https://doi.org/10.1016/j.jpba.2020.113777
Bykova AA, Malinovskaya LK, ShChomakhidze P, Trushina OV, Shaltaeva YR, Belyakov VV, Golovin AV, Pershenkov VS, Syrkin AL, Betelin VB (2019) “Exhaled breath analysis in diagnostics of cardiovascular diseases. Kardiologiia. 9(7):61–67. https://doi.org/10.18087/cardio.2019.7.10263
K Chandramouli P-Y Qian 2009 Proteomics: challenges, techniques and possibilities to overcome biological sample complexity Human Genomics and Proteomics 2009 https://doi.org/10.4061/2009/239204
Cheheltani R, Rosano JM, Wang B, Sabri AK, Pleshko N, Kiani MF (2012) Fourier transform infrared spectroscopic imaging of cardiac tissue to detect collagen deposition after myocardial infarction. J Biomed Opt 17(5):56014. https://doi.org/10.1117/1.JBO.17.5.056014
J-S Chen 2020 A localized surface plasmon resonance (LSPR) sensor integrated automated microfluidics for multiplex inflammatory biomarker detection Analyst 145 https://doi.org/10.1039/D0AN01201G
Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL, Weissleder R (2002) In vivo imaging of proteolytic activity in atherosclerosis. Circulation 105:2766–2771. https://doi.org/10.1161/01.CIR.0000017860.20619.23
Chen F, Yang J, Li Y, Wang H (2018) Circulating MicroRNAs as novel biomarkers for heart failure. Hellenic J Cardiol 59(4):209–214. https://doi.org/10.1016/j.hjc.2017.10.002
Cheng, Ziyi, Wang Rui, Jaebum Choo, and Fabiao Yu. 2019. “SERS-based immunoassay using gold-patterned array chips for rapid and sensitive detection of dual cardiac biomarkers” 144 (22). https://doi.org/10.1039/c9an01260e
Choo, Jaebum. 2014. “SERS-based competitive immunoassay of troponin I and CK-MB markers for early diagnosis of acute myocardial infarction” 50 (9). https://doi.org/10.1039/c3cc47850e.
Cikach FS Jr, Dweik RA (2012) Cardiovascular biomarkers in exhaled breath. Prog Cardiovasc Dis 55(1):34–43. https://doi.org/10.1016/j.pcad.2012.05.005
Colony AP (1987) Serum F-enolase in acute myocardial infarction. Heart 58:29–33. https://doi.org/10.1136/hrt.58.1.29
Cosentino N, Campodonico J, Moltrasio M, Lucci C, Milazzo V, Rubino M, De Metrio M et al (2021) Mitochondrial biomarkers in patients with ST-Elevation myocardial infarction and their potential prognostic implications : a prospective observational study. J Clin Med 10(275). https://doi.org/10.3390/jcm10020275
Cummins P, McGurk B, Littler WA (1981) Radioimmunoassay of human cardiac tropomyosin in acute myocardial infarction. Clin Sci 60(3):251–259. https://doi.org/10.1042/cs0600251
D’Aiuto F, Orlandi M, Gunsolley JC (2013) Evidence that periodontal treatment improves biomarkers and CVD outcomes. J Clin Periodontol 84(4 Suppl.):S85-105. https://doi.org/10.1902/jop.2013.134007
Danese Elisa, Montagnana Martina (2016) An historical approach to the diagnostic biomarkers of acute coronary syndrome. Annals of Translational Medicine. 4(10):1–11. https://doi.org/10.21037/atm.2016.05.19
Daniel Chan, Ng L, Leong. (2010) Biomarkers in acute myocardial infarction. BMC Medicine. 8(34):137–41. https://doi.org/10.31975/njbms.2018.8303
Daniel Chan, Ng L, Leong (2010) Biomarkers in acute myocardial infarction. National Journal of Basic Medical Sciences. 8(1):34. https://doi.org/10.31975/njbms.2018.8303
Danne O, Möckel M (2010) Choline in acute coronary syndrome: an emerging biomarker with implications for the integrated assessment of plaque vulnerability. Expert Rev Mol Diagn 10(2):159–171. https://doi.org/10.1586/erm.10.2
Danne Oliver, Lueders Christian, Storm Christian, Frei Ulrich, Möckel Martin (2007) “Whole blood choline and plasma choline in acute coronary syndromes: prognostic and pathophysiological implications.” Clinica Chimica Acta International Journal of Clinical Chemistry. 383(1–2):103–9. https://doi.org/10.1016/j.cca.2007.05.001
Dawson, Jesse, Matthew Walters, Christian Delles, Harald Mischak, and William Mullen. 2012. “Urinary proteomics to support diagnosis of stroke.” PloS One 7 (5). https://doi.org/10.1371/journal.pone.0035879
Dekker MS, Mosterd A, Van Arnoud WJ, ’T Hof, and Arno W. Hoes. (2010) Novel biochemical markers in suspected acute coronary syndrome: systematic review and critical appraisal. Heart 96:1001–1010. https://doi.org/10.1136/hrt.2009.189886
Delles C, Schiffer E, Von C, Peter K, Rossing P, Parving H-H, Dymott JA et al (2010) Urinary proteomic diagnosis of coronary artery disease : identification and clinical validation in 623 individuals. J Hypertens 28(11):2316–2322. https://doi.org/10.1097/HJH.0b013e32833d81b7
Dhingra R, Vasan RS (2017) Biomarkers in cardiovascular disease: statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med 27(2):123–133. https://doi.org/10.1016/j.tcm.2016.07.005
Diamantopoulos EJ, Andreadis EA, Vassilopoulos CV, Theodorides TG, Giannakopoulos NS, Chatzis NA, Christopoulou-Kokkinou VD (2003) Increased plasma plasminogen activator inhibitor-1 levels: a possible marker of hypertensive target organ damage. Clin Exp Hypertens 25(1):1–9. https://doi.org/10.1081/CEH-120017736
Ding T, Minghui Hong A, Richards M, Wong TI, Zhou X (2015) Quantification of a cardiac biomarker in human serum using extraordinary optical transmission (EOT). PLoS ONE 10:1–14. https://doi.org/10.1371/journal.pone.0120974
Doehner W, Landmesser U (2011) Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol 31(5):433–440. https://doi.org/10.1016/j.semnephrol.2011.08.007
Dritsa, Vasiliki. 2012. “FT-IR Spectroscopy in medicine.” Infrared Spectroscopy - Life and Biomedical Sciences, no. Figure 1. https://doi.org/10.5772/37049
Ean J, IERRE P, ESPRÉS D, ENOÎT B, AMARCHE L, ASCALE P, AURIÈGE M, ERNARD B, ANTIN C, ILLES G, AGENAIS RD, ITAL S, OORJANI M, AUL P, UPIEN JL (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334(15):952–957. https://doi.org/10.1056/NEJM199604113341504
Eckart RE, Uyehara CFT, Shry EA, Furgerson JL, Krasuski RA (2004) Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J Interv Cardiol 17(1):27–31. https://doi.org/10.1111/j.1540-8183.2004.00289.x
El-said WA, Fouad DM, El-safty SA (2016) Ultrasensitive label-free detection of cardiac biomarker myoglobin based on surface-enhanced Raman spectroscopy. Sens Actuators, B Chem 228:401–409. https://doi.org/10.1016/j.snb.2016.01.041
Fareed, J., D. A. Hoppensteadt, F. Leya, O. Iqbal, H. Wolf, and R. Bick. 1998. “Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes.” Clinical Chemistry 44 (8(B)): 1845–53. https://doi.org/10.1093/clinchem/44.8.1845
Fireman Rosa, Tatsuo Lauro (2007) An SPR immunosensor for human cardiac troponin T using specific binding avidin to biotin at carboxymethyldextranmodified gold chip. Clinica Chimica Acta 376:114–20. https://doi.org/10.1016/j.cca.2006.07.029
S Franciscis de L Metzinger R Serra 2016 The discovery of novel genomic, transcriptomic, and proteomic biomarkers in cardiovascular and peripheral vascular disease: the state of the art Biomed Res Int 2016 https://doi.org/10.1155/2016/7829174
Frishman WilliamH (2002) Biologic markers as predictors of cardiovascular disease. Am J Med 104(6):18S-27S. https://doi.org/10.1016/s0002-9343(98)00184-3
Garg P, Morris P, Fazlanie AL, Vijayan S, Dancso B, Dastidar AG, Plein S, Mueller C, Haaf P (2017) Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med 12(2):147–155. https://doi.org/10.1007/s11739-017-1612-1
Garza JT, Cote GL (2017) Collection method of SERS active nanoparticles for sensitive and precise measurements. Anal Chem 89(24):13120–13127. https://doi.org/10.1021/acs.analchem.7b02318
Getz GS, Reardon CA (2004) Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 15(3):261–267. https://doi.org/10.1097/01.mol.0000130092.54381.6b
Gruzdeva Olga, Dyleva Yulia, Uchasova Evgenya, Akbasheva Olga, Karetnikova Victoria (2019) Biological markers and cardiac remodelling following the myocardial infarction. Aging. 11(11):3523. https://doi.org/10.18632/aging.101994
Haas SL, Müller R, Fernandes A, Dzeyk-Boycheva K, Würl S, Hohmann J, Hemberger S et al (2010) Spectroscopic diagnosis of myocardial infarction and heart failure by Fourier transform infrared spectroscopy in serum samples. Appl Spectrosc 64(3):262–267. https://doi.org/10.1366/000370210790918508
Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J et al (2001) Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 44:333–339. https://doi.org/10.1007/s001250051623
Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348(12):2575–2577. https://doi.org/10.1056/nejmoa022600
Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD (2004) N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110:3206–3212. https://doi.org/10.1161/01.CIR.0000147611.92021.2B
Hemdahl A-L, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J (2006) Expression of neutrophil gelatinase – associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 26(1):136–142. https://doi.org/10.1161/01.ATV.0000193567.88685.f4
Hill J, Claire Heslop SF, Man P, Frohlich J, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD (2011) Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. Eur Heart J 32(15):1918–1925. https://doi.org/10.1093/eurheartj/ehr124
Hoefer IE, Steffens S, Ala-Korpela M, Bäck M, Badimon L, Bochaton-Piallat ML, Boulanger CM et al (2015) Novel methodologies for biomarker discovery in atherosclerosis. Eur Heart J 36(39):2635–2642. https://doi.org/10.1093/eurheartj/ehv236
Hu, Cunming. 2020. “SERS-based magnetic immunoassay for simultaneous detection of CTnI and DOI: https://doi.org/10.1039/D0AY01564D H-FABP using core-shell nanotags cunming.” Analytical Methods
Ibrahim W, Wilde M, Cordell R, Salman D, Ruszkiewicz D, Bryant L, Richardson M, Free RC, Zhao Bo, Yousuf A (2019) Assessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study. BMJ Open 9(3):e025486. https://doi.org/10.1136/bmjopen-2018-025486
Janckila AJ, Lin HF, Yi Ying Wu, Chih Hung Ku, Yang SP, Lin WS, Lee SH, Yam LT, Chao TY (2011) Serum tartrate-resistant acid phosphatase isoform 5a (TRACP5a) as a potential risk marker in cardiovascular disease. Clin Chim Acta 412(11–12):963–969. https://doi.org/10.1016/j.cca.2011.01.035
Jang HR, Wark AW, Baek SH, Chung BH, Lee HJ (2014) Ultrasensitive and ultrawide range detection of a cardiac biomarker on a surface plasmon resonance platform. ANALYTICAL BIOCHEMISTRY 86:814–19. https://doi.org/10.1021/ac4033565
Jeremias A, Michael C, Gibson (2005) Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 142:786–791. https://doi.org/10.7326/0003-4819-142-9-200505030-00015
Jerris HR, James HW, Mark S (1996) Multicenter study of creatine kinase-MB use: effect on chest pain clinical decision making. Acad Emerg Med 3:7–15. https://doi.org/10.1111/j.1553-2712.1996.tb03295.x
Johansson M, Ricci F, Aung N, Sutton R, Melander O, Fedorowski A (2018) Proteomic profiling for cardiovascular biomarker discovery in orthostatic hypotension. Hypertension 71(3):465–472. https://doi.org/10.1161/HYPERTENSIONAHA.117.10365
RV John T Devasia J Lukose N Mithun S Chidangil 2022 Micro - raman spectroscopy study of blood samples from myocardial infarction patients Lasers Med Sci 0123456789 https://doi.org/10.1007/s10103-022-03604-1
Kartha, V Bhaskaran, and Chidangil Santhosh. 2014. Biomedical Spectroscopy. Manipal University Press.
Khanmohammadi M, Mozaffari F, BagheriGarmarudi A, Babaei M, Rouchi (2015) Cardiovascular biodiagnosis by infrared spectroscopy through choline determination. Anal Methods 7(20):8561–8567. https://doi.org/10.1039/C5AY01153A
Kim Y-C, Kwon M-G (2011) Development of a surface plasmon resonance-based immunosensor for the rapid detection of cardiac troponin I. Biotech Lett 33:921–927. https://doi.org/10.1007/s10529-010-0509-0
Kim HJ, Yoo HS, Kim PK, Kim MR, Lee HW, Kim CW (2011) Comparative analysis of serum proteomes of patients with cardiovascular disease. Clin Biochem 44(2–3):178–184. https://doi.org/10.1016/j.clinbiochem.2010.09.027
Kleiman NS, Lakkis N, Cannon CP, Murphy SA, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E (2002) Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 40(6):1044–1050. https://doi.org/10.1016/S0735-1097(02)02119-8
Kneipp K, Harald Kneipp V, Kartha B, Manoharan R, Deinum G, Itzkan I, Dasari RR, Feld MS (1998) Detection and identification of a single DNA base molecule using surface-enhanced Raman scattering (SERS). Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics 57(6):6281–6284. https://doi.org/10.1103/PhysRevE.57.R6281
Koenig W, Khuseyinova N (2009) Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther 23(1):85–92. https://doi.org/10.1007/s10557-008-6135-6
Koenig W, Twardella D, Brenner H, Rothenbacher D (2005) Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51(2):321–327. https://doi.org/10.1373/clinchem.2004.041889
Kontush A (2016) Identifying new risk markers and potential targets: the value of the proteome. Cardiovasc Drugs Ther 30(1):13–18. https://doi.org/10.1007/s10557-016-6656-3
Kristensen LP, Larsen MR, Mickley H, Saaby L, Diederichsen ACP, Lambrechtsen J, Rasmussen LM, Overgaard M (2014) Plasma proteome profiling of atherosclerotic disease manifestations reveals elevated levels of the cytoskeletal protein vinculin. J Proteomics 101:141–153. https://doi.org/10.1016/j.jprot.2013.12.011
Kurita R, Yokota Y, Sato Y, Mizutani F, Niwa O (2006) On-chip enzyme immunoassay of a cardiac marker using a microfluidic device combined with a portable surface plasmon resonance system. Anal Chem 78(15):5525–5531. https://doi.org/10.1021/ac060480y
J Langer DJD Aberasturi J Aizpurua RA Alvarez-puebla B Auguie JJ Baumberg GC Bazan SEJ Bell ABoisen 2019 Present and future of surface-enhanced raman scattering ACS Nano 14 https://doi.org/10.1021/acsnano.9b04224
Laterza OF, Cameron SJ, Chappell D, Sokoll LJ, Green GB (2004) Evaluation of pregnancy-associated plasma protein a as a prognostic indicator in acute coronary syndrome patients. Clin Chim Acta 348:163–169. https://doi.org/10.1016/j.cccn.2004.05.022
Lee, Min-yi, Chun-hao Huang, Chao-jen Kuo, Chen-lung Steve Lin, and Wen-ter Lai. 2015. “Clinical proteomics identifies urinary CD14 as a potential biomarker for diagnosis of stable coronary artery disease.” PloS One 10 (2). https://doi.org/10.1371/journal.pone.0117169
Leon-mimila P, Wang J, Huertas-vazquez A (2019) Relevance of multi-omics studies in cardiovascular diseases. Frontiers in Cardiovascular Medicine 6:91. https://doi.org/10.3389/fcvm.2019.00091
Lerman A, McConnell JP (2008) Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Am J Cardiol 101:11F-22F. https://doi.org/10.1016/j.amjcard.2008.04.014
Lewandrowski, Kent, Ahchean Chen, and James Januzzi. 2002. “Cardiac markers for myocardial infarction. a brief review.” American Journal of Clinical Pathology 118 Suppl (Suppl 1): 93–99. https://doi.org/10.1092/87CMFCR7TXUXH11Y.
J Li H Li XuJinpeng X Zhao S Song Z Xue Y Seng 2021 Silica / antibody - conjugated microcomb electrode sensor for cardiac biomarker analysis Appl Phys A 127 https://doi.org/10.1007/s00339-020-04260-4
Limonte CP, Zelnick LR, Ruzinski J, Hoofnagle AN, Thadhani R, Melamed ML, Lee I-M et al (2021) Effects of long-term vitamin D and n-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes : secondary analyses from a randomised controlled trial. Diabetologia 64:437–447. https://doi.org/10.1007/s00125-020-05300-7
Lindsey ML, Mayr M, Gomes AV, Christian Delles D, Arrell K, Murphy AM, Lange RA et al (2015) Transformative impact of proteomics on cardiovascular health and disease: a scientific statement from the American Heart Association. Circulation 132(9):852–872. https://doi.org/10.1161/CIR.0000000000000226
Liyanage T, Andeep S (2017) Achieving biosensing at attomolar concentrations of cardiac troponin T in human biofluids by developing a label-free nanoplasmonic analytical assay. Analyst. https://doi.org/10.1039/C7AN00430C
Lukose J, Kulal V, Chidangil S, Sinha RK (2016) Smaller to larger biomolecule detection using a lab-built surface plasmon resonance based instrument. Laser Phys 26:105602. https://doi.org/10.1088/1054-660X/26/10/105602
J Lukose V Shetty M Ballal S Chidangil 2018 Real-time and rapid detection of Salmonella Typhimurium using an inexpensive lab-built surface plasmon resonance setup Laser PhysLett 15 https://doi.org/10.1088/1612-202X/aabed8
Lynch M, Barallobre-Barreiro J, Jahangiri M, Mayr M (2016) Vascular proteomics in metabolic and cardiovascular diseases. J Intern Med 280(4):325–338. https://doi.org/10.1111/joim.12486
Ma Li, Liu T, Li J, Guan M (2019) Detection of H-FABPA by novel SERS combined with magnetic reaction. Nanotechnology ACCEPTED. https://doi.org/10.1088/1361-6528/ab55c1
Mabbott S, Fernandes SC, Schechinger M, Cote GL, Karen Faulds R, Mace, and Duncan Graham. (2019) Detection of cardiovascular disease associated MiR-29a using paper-based microfluidics and surface enhanced raman scattering. Analyst. https://doi.org/10.1039/c9an01748h
Májek P, Reicheltová Z, Suttnar J, Malý M, Oravec M, Pečánková K, Dyr JE (2011) Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1. J Transl Med 9(84):1–7. https://doi.org/10.1186/1479-5876-9-84
Makin AJ, Chung NAY, Silverman SH, Lip GYH (2003) Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci 104(4):397–404. https://doi.org/10.1042/CS20020182
Marcondes-Braga FG, Batista GL, Bacal F, Gutz I (2016) Exhaled breath analysis in heart failure. Curr Heart Fail Rep 13(4):166–171. https://doi.org/10.1007/s11897-016-0294-8
Masson J, Obando L, Beaudoin S, Booksh K (2004) Sensitive and real-time fiber-optic-based surface plasmon resonance sensors for myoglobin and cardiac troponin I. Talanta 62:865–870. https://doi.org/10.1016/j.talanta.2003.09.032
McDonnell B, Hearty S, Leonard P, O’Kennedy R (2009) Cardiac biomarkers and the case for point-of-care testing. Clin Biochem 42(7–8):549–561. https://doi.org/10.1016/j.clinbiochem.2009.01.019
Moe KT, Wong P (2010) Current trends in diagnostic biomarkers of acute coronary syndrome. Annals of the Academy of Medicine 39(3):210. https://doi.org/10.2174/9781681084954117010012
Mokou M, Lygirou V, Vlahou A, Mischak H (2017) Proteomics in cardiovascular disease: recent progress and clinical implication and implementation. Expert Rev Proteomics 14(2):117–136. https://doi.org/10.1080/14789450.2017.1274653
Mora S, Rifai N, Buring JE, Ridker PM (2006) Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation 114(5):381–387. https://doi.org/10.1161/CIRCULATIONAHA.106.634089
Morrow DA, Sabatine MS, Brennan ML, De Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL (2008) Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 29(9):1096–1102. https://doi.org/10.1093/eurheartj/ehn071
Muscari A, Massarelli G, Puddu G, Palareti G, Legnani C, D’Atena T, Mazzuca A, Miniero R, Toscano V, Conte R, Puddu P (1995) Complement components and fibrinogen: correlations and association with previous myocardial infraction. Cardiology 86:232–237. https://doi.org/10.1159/000176879
Natarajan S, Jayaraj J, Duarte Miguel F, Prazeres (2021) A cellulose paper-based fluorescent lateral flow immunoassay for the quantitative detection of cardiac troponin I. Biosensors 11(49):1–12. https://doi.org/10.3390/bios11020049
Nidheesh R, Aswini Kumar Mohapatra V, Unnikrishnan VK, Kumar Sinha R, Nayak R, BaskaranKartha V, Chidangil S (2021) Breath analysis for the screening and diagnosis of diseases. Appl Spectrosc Rev 56(8–10):702–732. https://doi.org/10.1080/05704928.2020.1848857
Nidheesh, V R, Aswini Kumar Mohapatra, V Ka Unnikrishnan, Rajeev Kumar Sinha, Vasudevan Baskaran Kartha, and Santhosh Chidangil. 2021. “Design and development of a photoacoustic set up for breath analysis: a preliminary study.” In European Conference on Biomedical Optics, EM1A-30. Optica Publishing Group
Nidheesh VR, Kumar Mohapatra A, Unnikrishnan VK, Lukose J, BaskaranKartha V, Chidangil S (2022) “Post-COVID syndrome screening through breath analysis using electronic nose technology’’. Anal Bioanal Chem 414(12):3617–3624. https://doi.org/10.1007/s00216-022-03990-z
Okamoto F, Sohmiya K, Ohkaru Y, Kawamura K, Asayama K, Kimura H, Nishimura S, Ishii H, Sunahara N, Tanaka T (2000) Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem Lab Med 38(3):231–238. https://doi.org/10.1515/CCLM.2000.034
Ottani F, Galvani M (2001) Prognostic role of hemostatic markers in acute coronary syndromes patients. Clin Chim Acta 311:33–39. https://doi.org/10.1016/S0009-8981(01)00555-1
Zheng, Na, Tiantong Yang, Man Liang, Haidong Zhang, Liping Li, Ananda Sunnassee, and Liang Liu. 2010. “Characterization of protein in old myocardial infarction by FTIR micro-spectroscopy.” Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban. 30(4): 546–50. https://doi.org/10.1007/s11596-010-0466-9.
Owlstone, under Science & Research (2022) The Potential of Breath Biomarkers for Cardiometabolic Diseases. 28 March. 2022. https://www.owlstonemedical.com/about/blog/2022/mar/28/breath-biomarkers-cardiometabolic/
Panteghini M (2004) Role and importance of biochemical markers in clinical cardiology. Eur Heart J 25:1187–1196. https://doi.org/10.1016/j.ehj.2004.04.026
A Patil KS Choudhari VK VijendraPrabhu SB Unnikrishnan KM Pai VB Kartha C Santhosh 2012 Highly sensitive high performance liquid chromatography-laser induced fluorescence for proteomics applications ISRN Spectroscopy 2012 https://doi.org/10.5402/2012/643979
Patel JV, Lim HS, Varughese GI, Hughes EA, Lip GYH (2008) Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med 40(3):215–222. https://doi.org/10.1080/07853890701779586
Peetz D, Schweigert R, Schollmayer C, Steinbach K, Lackner KJ, Post F, Schinzel H, Dati F, Noll F (2005) Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med 43(12):1351–1358. https://doi.org/10.1515/CCLM.2005.231
Percy AJ, Byrns S, Chambers AG, Borchers CH (2013) Targeted quantitation of CVD-linked plasma proteins for biomarker verification and validation. Expert Rev Proteomics 10(6):567–578. https://doi.org/10.1586/14789450.2013.856763
Pirouzpanah Bagher, Mohammad. et al (2019) MiRNA-21: A potential biomarker for the diagnosis of acute myocardial infraction”. International J Biomed Public Health 2(2):41–45. https://doi.org/10.22631/ijbmph.2019.164756.1087
Pischon T (2009) Use of obesity biomarkers in cardiovascular epidemiology. Dis Markers 26(5–6):247–263. https://doi.org/10.3233/DMA-2009-0634
Pletsch-borba L, Grafetstätter M, Hüsing A, González S, Kloss M, Groß M-L, Johnson T et al (2019) Biomarkers of vascular injury in relation to myocardial infarction risk : a population-based study. Sci Rep 9(1):1–9. https://doi.org/10.1038/s41598-018-38259-y
Pourali A, Reza M, Barar J, Pavon-djavid G (2021) Trends in analytical chemistry voltammetric biosensors for analytical detection of cardiac troponin biomarkers in acute myocardial infarction. Trends Anal Chem 134:116123. https://doi.org/10.1016/j.trac.2020.116123
Primo, Emiliano N, Marcelo J Kogan, Hugo E Verdejo, Soledad Bollo, D Rubianes, and Gustavo A Rivas. 2018. Label-free graphene oxide-based surface plasmon resonance immunosensor for the quantification of galectin3, a novel cardiac biomarker. Applied Materials & Interfaces. 10 (28)
Qureshi A, Gurbuz Y, Niazi JH (2012) Biosensors for cardiac biomarkers detection: a review. Sens Actuators B Chem 171–172:62–76. https://doi.org/10.1016/j.snb.2012.05.077
Rao et al. 2020 S Rao R John VK Ajeetkumar Patil SD Unnikrishnan KM George RO Pai VB Tom Devasia Kartha S Chidangil 2020 “Optical biopsy and optical pathology:affordable health care under low-resource settings” J of Biomedical Photonics and Eng. 6 2 020309 https://doi.org/10.18287/JBPE20.06.020309
Regan B, Kennedy RO, Collins D (2018) Point-of-care compatibility of ultra-sensitive detection techniques for the cardiac biomarker troponin I — challenges and potential value. Biosensors 8(114):1–32. https://doi.org/10.3390/bios8040114
Ridker PM (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107(3):363–369. https://doi.org/10.1161/01.CIR.0000053730.47739.3C
Rizzo M, Macario AJL, Conway E, de Macario I, Gouni-Berthold HK, Berthold GB, Rini GZ, Cappello F (2011) Heat shock protein-60 and risk for cardiovascular disease. Curr Pharm Des 17(33):3662–3668. https://doi.org/10.2174/138161211798220981
Ruwanpathirana T, Owen A, Reid CM (2015) Review on cardiovascular risk prediction. Cardiovasc Ther 33(2):62–70. https://doi.org/10.1111/1755-5922.12110
Sahu P, Neha Pinkalwar Rd, Dubey SP, Chatterjee S, Chatterjee T (2011) Biomarkers: an emerging tool for diagnosis of a disease and drug development. Asian J Pharm Sci 1(1):9–16
Sala A, Anderson DJ, Brennan PM, Butler HJ, Cameron JM, Jenkinson MD, Rinaldi C, Theakstone AG, Baker MJ (2020) Biofluid diagnostics by FTIR spectroscopy: a platform technology for cancer detection. Cancer Lett 477:122–130. https://doi.org/10.1016/j.canlet.2020.02.020
Sato T, Yoshinouchi T, Sakamoto T, Fujieda H, Murao S, Sato H, Kobayashi H, Ohe T (1997) Hepatocyte growth factor (HGF): a new biochemical marker for acute myocardial infarction. Heart Vessels 12:241–246. https://doi.org/10.1007/BF02766790
Satoh K, Shimizu T, Ikeda S, Kikuchi N, Satoh T, Kurosawa R, Nogi M et al (2019) Identification of adipsin as a novel prognostic biomarker in patients with coronary artery disease. J Am Heart Assoc. https://doi.org/10.1161/JAHA.119.013716
Schneider MV, Orchard S (2011) Omics technologies, data and bioinformatics principles. Bioinformatics for Omics Data, Humana Press. https://doi.org/10.1007/978-1-61779-027-0_1
Shen X, Young R, Canty JM, Jun Qu (2014) Quantitative proteomics in cardiovascular research: global and targeted strategies. Proteomics - Clinical Applications 8(7–8):488–505. https://doi.org/10.1002/prca.201400014
Shorie M, Kumar V, Kaur H, Singh K, Tomer VK, Sabherwal P (2018) Plasmonic DNA Hotspots Made from Tungsten Disulfide Nanosheets and Gold Nanoparticles for Ultrasensitive Aptamer-Based SERS Detection of Myoglobin. Microchim Acta 2:1–8. https://doi.org/10.1007/s00604-018-2705-x
Sobotka PA, Gupta DK, Lansky DM, Costanzo MR, Zarling EJ (1994) Breath pentane is a marker of acute cardiac allograft rejection. The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation 13(2):224–29
Stepczynska A, Schanstra JP, Mischak H (2016) Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. Bioanalysis 8(5):439–455. https://doi.org/10.4155/bio.16.8
Strimbu K, Tavel JA (2010) What Are Biomarkers? Curr Opin HIV AIDS 5(6):463–466. https://doi.org/10.1097/COH.0b013e32833ed177
Su Yu, Shuting Xu, Zhang J, Chen X-J, Jiang L-P, Zheng T, Zhu J-J et al (2018) Plasmon near-field coupling of bimetallic nanostars and hierarchical bimetallic SERS ‘hot field’: toward ultrasensitive simultaneous detection of multiple cardiorenal syndrome biomarkers. Anal Chem. https://doi.org/10.1021/acs.analchem.8b03573
Sujatha LR, Krishnanand BR, Mahato KK, Kartha VB, Santhosh C (2006) Protein profile study of the cervical cancer using HPLC- LIF. Spie Procedings 6092:1–10. https://doi.org/10.1117/12.647292
Tadepalli, Sirimuvva, Zhifeng Kuang, Qisheng Jiang, Keng-ku Liu, and Marilee A Fisher. 2015. “Peptide functionalized gold nanorods for the sensitive detection of a cardiac biomarker using plasmonic paper devices.” Nature Publishing Group, no. March: 1–11. https://doi.org/10.1038/srep16206.
Tan Y, Ji X, Mo Z, Zhou Y (2019) Serum YKL-40 positively correlates with MMP-9 and CRP in patients with acute ST segment elevation myocardial infarction following emergency treatment. Medicine 98(47):1–5. https://doi.org/10.1097/MD.0000000000017950
Tang L, Casas J (2014) Quantification of cardiac biomarkers using label-free and multiplexed gold nanorod bioprobes for myocardial infarction diagnosis. Biosensors and Bioelectronic 61:70–75. https://doi.org/10.1016/j.bios.2014.04.043
Tang L, Casas J, Venkataramasubramani M (2013) Magnetic nanoparticle mediated enhancement of localized surface plasmon resonance for ultrasensitive bioanalytical assay in human blood plasma. Anal Chem 85:1431–1439. https://doi.org/10.1021/ac302422k
Tehrani DM, Wong ND (2015) Cardiovascular disease risk assessment: review of established and newer modalities. Curr Treat Options Cardiovasc Med 17(12):57. https://doi.org/10.1007/s11936-015-0420-z
Toshio N, Yasuaki N (2017) Adrenomedullin as a biomarker of heart failure. Heart Fail Clin 14(1):49. https://doi.org/10.1016/j.hfc.2017.08.006
Troyanov S, Hébert MJ, Masse M, Vigneault N, Sirois I, Madore F (2003) Soluble Fas: a novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis 41(5):1043–1051. https://doi.org/10.1016/S0272-6386(03)00202-6
Tsai J, Jung C, Ikoma T, Yoshioka T, Cross JS, Chang S-J, Tsai J-Z, Tanaka J (2011) Surface plasmon resonance biosensor with high anti-fouling ability for the detection of cardiac marker troponin T. Anal Chim Acta 703(1):80–86. https://doi.org/10.1016/j.aca.2011.07.019
CW Tsao AW Aday ZI Almarzooq A Alonso AZ Beaton MS Bittencourt AK Boehme et al 2022 Heart disease and stroke statistics-2022 update: a report from the American Heart Association Circulation 145 https://doi.org/10.1161/CIR.0000000000001052
Tsimikas, Sotirios. 2006. “Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease.” American Journal of Cardiology 98 (11 SUPPL.). https://doi.org/10.1016/j.amjcard.2006.09.015.
Tuñón J, Barbas C, Blanco-Colio L, Burillo E, Lorenzo Ó, Martín-Ventura JL, Más S, Rupérez FJ, Egido J (2016) Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential. Expert Rev Proteomics 13(9):857–871. https://doi.org/10.1080/14789450.2016.1217775
Tuteja S, Rader DJ (2012) Genomic medicine in the prevention and treatment of atherosclerotic cardiovascular disease. Pers Med 9(4):395–404. https://doi.org/10.2217/pme.12.34
Uji Y, Sugiuchi H, Okabe H (1991) Measurement of human ventricular myosin light chain-1 by monoclonal solid-phase enzyme immunoassay in patients with acute myocardial infarction. J Clin Lab Anal 5(4):242–246. https://doi.org/10.1002/jcla.1860050404
Urbonaviciene G, Frystyk J, Flyvbjerg A, Henneberg EW, Lindholt JS (2010) Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease. Atherosclerosis 210(2):619–624. https://doi.org/10.1016/j.atherosclerosis.2009.12.030
Vahl N, Klausen I, Christiansen JS, Jùrgensen JOL (1999) Growth hormone (GH) status is an independent determinant of serum levels of cholesterol and triglycerides in healthy adults. Clin Endocrinol 51:309–316. https://doi.org/10.1046/j.1365-2265.1999.00772.x
Vasan RS (2006) Basic science for clinicians biomarkers of cardiovascular disease molecular basis and practical considerations. Circulation 113(19):2335–2362. https://doi.org/10.1161/CIRCULATIONAHA.104.482570
Velagaleti RS, Gona P, Sundström J, Larson MG, Siwik D, Colucci WS, Benjamin EJ, Vasan RS (2010) Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality. Arterioscler Thromb Vasc Biol 30(11):2283–2288. https://doi.org/10.1161/ATVBAHA.110.208462
Venkatakrishna K, Kartha VB, Pai KM, Murali C, Krishna (2003) HPLC-LIF for early detection of oral cancer. Curr Sci 84(4):551–557
Wang Z, Zhang M, Wang Z, Li Q, Wang Z (2020) Mechanistic role of MiR-24 and MiR-34 in progression in myocardial infarction. Journal of King Saud University - Science 32(1):1254–1257. https://doi.org/10.1016/j.jksus.2019.11.012
X-Y Wang F Zhang C Zhang L-R Zheng J Yang 2020a The biomarkers for acute myocardial infarction and heart failure Biomed Res Int 2020 https://doi.org/10.1155/2020/2018035
Witte DR, Broekmans WMR, Kardinaal AFM, Klöpping-Ketelaars IAA, Van Poppel G, Bots ML, Kluft C, Princen JMG (2003) Soluble intercellular adhesion molecule 1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis 170:147–153. https://doi.org/10.1016/S0021-9150(03)00253-3
Wu Q, Sun Y, Zhang Di, Li S, Zhang Y, Ma P, Yang Yu, Wang X, Song D (2017) Ultrasensitive magnetic field-assisted surface plasmon resonance immunoassay for human cardiac troponin I. Biosensors and Bioelectronic 96:288–293. https://doi.org/10.1016/j.bios.2017.05.023
Xiuli Fu, Yunqing W, Yongming L, Liu Huitao Fu, Longwen JW, Jingwen Li, Peihai W, Lingxin C (2018) Graphene oxide/gold nanoparticles-based amplification method for SERS immunoassay of cardiac troponin I. Analyst 2013:1–3. https://doi.org/10.1039/C8AN02022A
Yang J, Liao X, Yin W, Wang Bo, Yue J, Bai L (2021) Elevated cardiac biomarkers may be effective prognostic predictors for patients with COVID-19: a multicenter, observational study. Am J Emerg Med 39(37):34–41. https://doi.org/10.1016/j.ajem.2020.10.013
Yardim M (2019) Biomarkers in acute myocardial infarction : current perspectives. Vascular Health and Risk Management 15:1–10. https://doi.org/10.2147/VHRM.S166157
Yokokawa T, Sugano Y, Shimouchi A, Shibata A, Nakayama T, Ohara T, Jinno N, Kanzaki H, Anzai T (2016) A case of acute decompensated heart failure evaluated by series of exhaled acetone concentrations as noninvasive biomarker of heart failure severity. Int J Cardiol 204:112–113. https://doi.org/10.1016/j.ijcard.2015.11.173
Yu P, Zhao Ji, Jiang H, Liu M, Yang X, Zhang B, Ying Yu et al (2018) Neural cell adhesion molecule-1 may be a new biomarker of coronary artery disease. Int J Cardiol 257:238–242. https://doi.org/10.1016/j.ijcard.2017.12.040
Zhang X, Wei D, Yap Y, Li L, Guo S, Chen F (2007) Mass spectrometry-based ‘“ omics ”’ technologies in cancer diagnostics. Mass Spectrom Rev 26(3):403–431. https://doi.org/10.1002/mas
Zhang Di, Huang Li, Liu B, Enben Su, Chen H-Y, Zhongze Gu (2018) Quantitative detection of multiplex cardiac biomarkers with encoded SERS nanotags on a single T line in lateral flow assay. Sens Actuators, B Chem 277:502–509. https://doi.org/10.1016/j.snb.2018.09.044
Zhang D, Wang B, Ma M, Kun Yu, Zhang Q, Zhang X (2019) LncRNA HOTAIR protects myocardial infarction rat by sponging MiR-519d-3p. J Cardiovasc Transl Res 12(3):171–183. https://doi.org/10.1007/s12265-018-9839-4
Funding
Open access funding provided by Manipal Academy of Higher Education, Manipal. The authors are thankful to the Manipal Academy of Higher Education, Department of Science and Technology (DST), Govt. of India, and VGST, Govt. of Karnataka, for the HPLC facility. Ms. Reena V. John is thankful for the scholarship awarded by the Minority Department of Karnataka State.
Author information
Authors and Affiliations
Contributions
Material preparation, data collection, analysis, and first draft was written by Reena V John. Nidheesh V R contributed to material preparation and Tom Devasiya has provided clinical samples. Study conception and design is done by Santhosh Chidangil. All authors commented on previous versions of the manuscript and all authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval
Ethical clearance (IEC 346/2017) for the study is obtained from Institutional Ethical Committee (IEC), Kasturba Medical College, Manipal, and clinical trial registry of India – ICMR (CTRI/2017/08/009500), India.
Consent to participate
A participant information sheet was distributed and informed consent was obtained from the volunteers before collecting the blood sample.
Consent for publication
Not applicable.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
John, R.V., Devasiya, T., V.R., N. et al. Cardiovascular biomarkers in body fluids: progress and prospects in optical sensors. Biophys Rev 14, 1023–1050 (2022). https://doi.org/10.1007/s12551-022-00990-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12551-022-00990-2